secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0001664710-25-000008
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros-Takeda license for elritercept effective; $200M upfront payment triggered
-------------------------------------------------------------------------------

- Global license agreement with Takeda (TSE:4502/NYSE:TAK) for elritercept became effective Jan 16, 2025.
- Upfront payment of $200.0 million from Takeda to Keros was triggered upon effectiveness.
- Agreement was previously announced on Dec 3, 2024; effectiveness followed HSR waiting period expiration.
- Elritercept is a clinical-stage therapy targeting TGF-ß family signaling disorders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000008/0001664710-25-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000008/kros-20250116.htm
  HTML page:      https://secwatch.observer/filing/0001664710-25-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer